Welcome to our dedicated page for Haemonetics Mass news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics Mass stock.
Haemonetics Corporation (NYSE: HAE) is a global medical technology company whose news flow centers on hospital technologies, plasma collection systems and blood center products. Company communications describe a focus on improving the quality, effectiveness and efficiency of health care, so news items often highlight developments that affect these areas.
Investors following HAE news can expect regular announcements about quarterly financial results, including the availability of earnings releases and details for conference calls and webcasts with investors and analysts. These updates are typically accompanied by Form 8-K filings that furnish the related press releases and summarize results for specific fiscal quarters.
Haemonetics also issues news about its participation in healthcare investment conferences, such as presentations at the J.P. Morgan Healthcare Conference and the Goldman Sachs Global Healthcare Conference. These events provide additional context for the company’s strategy and operations in the medical technology space.
A notable category of news involves corporate transactions and interventional technologies. For example, Haemonetics announced the acquisition of Vivasure Medical Limited, a Galway, Ireland-based company focused on next-generation percutaneous vessel closure technology. Press releases describe how Vivasure’s PerQseal Elite system, which uses a proprietary bioabsorbable patch for large-bore arterial and venous closure, is intended to expand Haemonetics’ range of closure devices and its presence in the large-bore closure market.
By monitoring the Haemonetics news page, readers can track earnings communications, conference participation, regulatory and acquisition-related updates, and other material events disclosed through press releases and SEC filings. This provides a consolidated view of developments affecting HAE within the surgical and medical instrument manufacturing industry.
Haemonetics Corporation (NYSE: HAE) will release its fourth quarter and fiscal year 2021 financial results on May 13, 2021, at 6:00 am EDT. An investor conference call will follow at 8:00 am EDT to discuss the results. Interested participants can join the call via a toll-free number for U.S. and Canada or an international line, with a required conference ID of 8694785. A live webcast will also be available on the company's investor relations website, and a replay will be accessible for one year starting at 11:00 am EDT on the same day.
Haemonetics Corporation (NYSE: HAE) announced that CSL Plasma will not renew their Supply Agreement for PCS2® Plasma Collection System devices in the U.S., effective June 2022. This decision, driven by CSL's internal strategy, will affect approximately $117 million in revenue, which is 11.8% of Haemonetics' total revenue. The company anticipates a $25 million impairment charge and an additional $7 million in expenses in Q4 FY2021. Despite this, Haemonetics remains committed to supporting CSL in other markets and expects continued growth in U.S. plasma collections.
Haemonetics Corporation (NYSE: HAE) has priced a private offering of $435 million aggregate principal amount of 0.00% Convertible Senior Notes due March 2026. This offering, increased from a previous $425 million, is set to close on March 5, 2021. The notes will not bear regular interest and are convertible into common stock at an initial price of approximately $175.34, a 40% premium over the last reported sale. Haemonetics estimates net proceeds of about $423.3 million, for debt reduction and other corporate purposes.
Haemonetics Corporation (NYSE: HAE) announced a private offering of $425 million in Convertible Senior Notes due 2026. The offering is subject to market conditions and is targeted at qualified institutional buyers. An additional $63.75 million may also be offered. The notes will be unsecured and allow conversion into cash or stock. Proceeds will be used for capped call transactions and to reduce existing debt. However, there are risks associated with market conditions and the effectiveness of the capped call transactions.
Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, the President and CEO, will present at the Jefferies Plasma Summit on March 11, 2021, at 10:45 a.m. ET. The presentation will be accessible live via webcast, with a replay available for one month. Haemonetics is focused on delivering innovative medical products and solutions, primarily in blood and plasma collection, surgical services, and hospital transfusions.
Haemonetics Corporation (NYSE: HAE) announced the availability of its third-quarter fiscal 2021 financial results, concluding on December 26, 2020. A conference call is scheduled for February 2, 2021, at 8:00 a.m. ET, to discuss the results and address investor queries. The earnings release, analytical tables, and details regarding the acquisition of Cardiva Medical, Inc. have been posted on the Investor Relations website. The company's innovative healthcare solutions aim to enhance patient care while reducing healthcare costs.
Haemonetics Corporation (NYSE: HAE) supports the FDA's new guidance on viscoelastic testing during the COVID-19 pandemic. The company is modifying labeling for its TEG® 5000 and TEG® 6s hemostasis analyzers to enhance patient care. These analyzers provide critical insights into blood clotting, addressing coagulopathy associated with COVID-19, which can lead to severe complications. Haemonetics aims to optimize blood resource utilization while ensuring that healthcare professionals have access to necessary technologies during this crisis.
Haemonetics (NYSE: HAE) has announced a definitive agreement to acquire Cardiva Medical for $475 million upfront, plus $35 million contingent on sales growth. This strategic acquisition aims to enhance Haemonetics' offerings in interventional cardiology and electrophysiology markets. The deal is expected to generate $65-$75 million in revenue in its first fiscal year but may dilute adjusted net earnings by $0.15 to $0.20 in fiscal 2022. The acquisition is projected to break even on earnings by fiscal 2023 and deliver a 10% return on invested capital by year five.
Haemonetics Corporation (NYSE: HAE) will release its third quarter fiscal year 2021 financial results on February 2, 2021, at 6:00 am EDT. Following this, a conference call for investors and analysts will occur at 8:00 am EDT on the same day to discuss the results. Access to the call is available via toll-free and international numbers, with a conference ID required. A live webcast will also be available on Haemonetics' investor relations website, with a replay accessible from February 2 to February 10, 2021.
Haemonetics Corporation (NYSE:HAE) has released its financial results for the second quarter of fiscal 2021, concluding on September 26, 2020. The earnings release and results tables are accessible on its Investor Relations website, along with a scheduled conference call for investors on November 4, 2020, at 8 a.m. EST. Key financial metrics and strategic updates are expected to be discussed during this call. Investors can also view the live webcast for detailed insights into the company's performance.